Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

This publication has 21 references indexed in Scilit:

• What's your treatment option in a patient with impending respiratory failure due to disseminated lung cancer?
  Respiratory Medicine CME, 2008
• The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
  Proceedings of the National Academy of Sciences, 2008
• Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
  British Journal of Cancer, 2007
• Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2007
• Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
  Clinical Cancer Research, 2006
• Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions
  Journal of Clinical Oncology, 2005
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  PLOS Medicine, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2004
• The role of EGFR inhibitors in nonsmall cell lung cancer
  Current Opinion in Oncology, 2004